Mounjaro vs Ozempic: Which Is Better for Weight Loss and Diabetes?

Q: Can I take Mounjaro or Ozempic for weight loss without diabetes?

Both have weight-loss-specific brands: Mounjaro is sold as Zepbound and Ozempic as Wegovy for chronic weight management. These are FDA-approved for weight loss in adults with BMI 30+ (or 27+ with weight-related conditions). Some doctors prescribe Mounjaro or Ozempic off-label for weight loss.

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both once-weekly injectable medications approved for type 2 diabetes. Many patients use them for weight loss — Mounjaro off-label for weight loss (or as its weight-loss-specific brand Zepbound), and Ozempic off-label (or as its weight-loss brand Wegovy).

In a head-to-head trial (SURPASS-2), Mounjaro produced more weight loss and better blood sugar control than Ozempic at all dose levels.

Side-by-Side Comparison

	Mounjaro	Ozempic
Generic name	Tirzepatide	Semaglutide
Manufacturer	Eli Lilly	Novo Nordisk
FDA approved for	Type 2 diabetes (2022)	Type 2 diabetes (2017)
Weight loss brand	Zepbound (approved 2023)	Wegovy (approved 2021)
Mechanism	Dual agonist: GLP-1 + GIP	Single agonist: GLP-1
Doses available	2.5, 5, 7.5, 10, 12.5, 15 mg	0.25, 0.5, 1, 2 mg
Administration	Once-weekly injection (pre-filled pen)	Once-weekly injection (pre-filled pen)
List price	~$1,059/month	~$935/month
Oral option	No	Yes (Rybelsus)

What Each Drug Is

Mounjaro (Tirzepatide)

Mounjaro is a dual GLP-1/GIP receptor agonist — the first drug in its class to target two incretin hormones simultaneously. It was FDA-approved for type 2 diabetes in 2022. The same molecule is sold as Zepbound specifically for weight loss.

Ozempic (Semaglutide)

Ozempic is a GLP-1 receptor agonist approved for type 2 diabetes since 2017. It is one of the most prescribed diabetes medications worldwide. The same molecule at a higher dose (2.4 mg) is sold as Wegovy for weight loss, and an oral version (Rybelsus) is available for diabetes.

For a detailed molecular comparison, see Tirzepatide vs Semaglutide.

Weight Loss Results

Drug	Trial	Duration	Weight Loss
Mounjaro 15 mg	SURMOUNT-1 (obesity)	72 weeks	-22.5%
Mounjaro 10 mg	SURMOUNT-1 (obesity)	72 weeks	-21.4%
Mounjaro 5 mg	SURMOUNT-1 (obesity)	72 weeks	-16.0%
Mounjaro (vs Ozempic)	SURPASS-2 (T2D)	40 weeks	-12.4% (15 mg)
Ozempic 1 mg (vs Mounjaro)	SURPASS-2 (T2D)	40 weeks	-6.2%
Wegovy 2.4 mg	STEP 1 (obesity)	68 weeks	-14.9%

In the SURPASS-2 head-to-head trial for type 2 diabetes, Mounjaro at all three doses (5, 10, 15 mg) produced more weight loss than Ozempic 1 mg. The highest dose produced roughly twice the weight loss of Ozempic.

Diabetes Management

Both drugs are highly effective for type 2 diabetes, but Mounjaro has shown superior glucose control.

Outcome	Mounjaro (SURPASS-2)	Ozempic (SURPASS-2)
HbA1c reduction (max dose)	-2.58%	-1.86%
HbA1c below 7.0%	Up to 92%	81%
HbA1c below 5.7% (normal)	Up to 46%	19%
Weight loss	-12.4 kg (15 mg)	-6.2 kg

Nearly half of patients on Mounjaro 15 mg reached a normal HbA1c (below 5.7%) — an outcome rarely seen with diabetes medications. Ozempic achieved this in 19% of patients.

Their Weight Loss Branded Versions

Both drugs have FDA-approved weight-loss-specific brands:

Mounjaro → Zepbound (tirzepatide for obesity, approved November 2023)
Ozempic → Wegovy (semaglutide for obesity, approved June 2021)

The active ingredient is the same — the difference is the indication, dosing, and insurance coverage. For a detailed comparison of the weight loss versions, see Zepbound vs Wegovy.

Side Effects

Side Effect	Mounjaro (SURPASS-2)	Ozempic (SURPASS-2)
Nausea	12-22%	18%
Diarrhea	12-16%	12%
Vomiting	2-8%	8%
Decreased appetite	5-11%	9%
Constipation	5-7%	4%
Discontinuation (AEs)	3-7%	5%

Both drugs have similar GI side effect profiles. Side effects are most common during dose escalation and typically improve at maintenance doses. Gradual titration is used with both drugs to minimize GI symptoms.

Cost

	Mounjaro	Ozempic
List price	~$1,059/month	~$935/month
Direct pricing	LillyDirect: ~$550/mo	Not available
Manufacturer savings	Lilly savings card	Novo savings card
Insurance coverage (T2D)	Growing (formulary-dependent)	Broad (established since 2017)
Insurance coverage (weight loss)	As Zepbound (growing)	As Wegovy (broader)

Ozempic has broader insurance coverage for type 2 diabetes due to its longer time on the market. Mounjaro's coverage is growing rapidly. For weight loss, insurance coverage remains challenging for both (as Zepbound and Wegovy respectively).

The Next Generation: Retatrutide

Retatrutide is Eli Lilly's next-generation triple agonist — targeting GLP-1, GIP, and glucagon receptors simultaneously. In Phase 3 trials, it produced 28.7% body weight loss, exceeding both Mounjaro and Ozempic. It is not yet FDA-approved (expected 2027).

Learn more: Retatrutide vs Mounjaro | What Is Retatrutide?

Frequently Asked Questions

Is Mounjaro better than Ozempic for weight loss?

In the SURPASS-2 head-to-head trial, Mounjaro produced approximately twice the weight loss of Ozempic at maximum doses. In the separate SURMOUNT-5 trial (comparing their weight loss versions), tirzepatide produced -20.2% vs semaglutide's -13.7%. For weight loss, the evidence favors Mounjaro/tirzepatide.

Is Mounjaro better than Ozempic for type 2 diabetes?

In SURPASS-2, Mounjaro was superior to Ozempic on both HbA1c reduction and weight loss. Up to 46% of Mounjaro patients achieved a normal HbA1c (below 5.7%) vs 19% on Ozempic. Both are highly effective, but Mounjaro showed stronger results.

Can I take Mounjaro or Ozempic for weight loss without diabetes?

Both have weight-loss-specific brands: Mounjaro is sold as Zepbound and Ozempic as Wegovy for chronic weight management. These are FDA-approved for weight loss in adults with BMI 30+ (or 27+ with weight-related conditions). Some doctors prescribe Mounjaro or Ozempic off-label for weight loss.

How much does Mounjaro cost vs Ozempic?

Mounjaro lists at approximately $1,059/month; Ozempic at approximately $935/month. Lilly offers LillyDirect pricing at ~$550/month. Both manufacturers offer savings cards. Actual out-of-pocket cost depends heavily on insurance coverage.

Does Ozempic come in a pill?

Yes. Semaglutide is available as an oral tablet under the brand name Rybelsus for type 2 diabetes, and as oral Wegovy for weight loss (approved 2025). Mounjaro is currently injection-only.

Sources

Frías, J.P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. DOI: 10.1056/NEJMoa2107519
Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038
Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources